skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 95  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives
Material Type:
Article 		Add to My Research

Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives

BioScience Trends, 2017/02/28, Vol.11(1), pp.110-114 [Peer Reviewed Journal]

2017 International Research and Cooperation Association for Bio & Socio-Sciences Advancement ;ISSN: 1881-7815 ;EISSN: 1881-7823 ;DOI: 10.5582/bst.2016.01221 ;PMID: 28123146

Full text available

Citations Cited by
2
Harnessing NK Cells for Cancer Treatment
Harnessing NK Cells for Cancer Treatment
Material Type:
Article 		Add to My Research

Harnessing NK Cells for Cancer Treatment

Frontiers in immunology, 2019-12, Vol.10, p.2836-2836 [Peer Reviewed Journal]

Copyright © 2019 Minetto, Guolo, Pesce, Greppi, Obino, Ferretti, Sivori, Genova, Lemoli and Marcenaro. ;COPYRIGHT 2019 Frontiers Research Foundation ;Copyright © 2019 Minetto, Guolo, Pesce, Greppi, Obino, Ferretti, Sivori, Genova, Lemoli and Marcenaro. 2019 Minetto, Guolo, Pesce, Greppi, Obino, Ferretti, Sivori, Genova, Lemoli and Marcenaro ;ISSN: 1664-3224 ;EISSN: 1664-3224 ;DOI: 10.3389/fimmu.2019.02836 ;PMID: 31867006

Full text available

Citations Cited by
3
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
Material Type:
Article 		Add to My Research

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes

Cancers, 2020-11, Vol.12 (12), p.3504 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12123504 ;PMID: 33255582

Full text available

Citations Cited by
4
Harnessing Immune Response in Acute Myeloid Leukemia
Harnessing Immune Response in Acute Myeloid Leukemia
Material Type:
Article 		Add to My Research

Harnessing Immune Response in Acute Myeloid Leukemia

Journal of clinical medicine, 2023-09, Vol.12 (18), p.5824 [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm12185824

Full text available

Citations Cited by
5
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3 -ITD in NPM1 Mutated AML, Irrespectively of FLT3 -ITD Allelic Burden
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3 -ITD in NPM1 Mutated AML, Irrespectively of FLT3 -ITD Allelic Burden
Material Type:
Article 		Add to My Research

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3 -ITD in NPM1 Mutated AML, Irrespectively of FLT3 -ITD Allelic Burden

Cancers, 2020-12, Vol.13 (1), p.34 [Peer Reviewed Journal]

2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13010034 ;PMID: 33374216

Full text available

Citations Cited by
6
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
Material Type:
Article 		Add to My Research

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

Frontiers in immunology, 2021-11, Vol.12, p.753890-753890 [Peer Reviewed Journal]

Copyright © 2021 Guolo, Minetto, Pesce, Ballerini, Clavio, Cea, Frello, Garibotto, Greppi, Bozzo, Miglino, Passannante, Marcolin, Tedone, Colombo, Mangerini, Bo, Ruzzenenti, Carlier, Serio, Luchetti, Dominietto, Varaldo, Candiani, Agostini, Ravetti, Del Zotto, Marcenaro and Lemoli. ;Copyright © 2021 Guolo, Minetto, Pesce, Ballerini, Clavio, Cea, Frello, Garibotto, Greppi, Bozzo, Miglino, Passannante, Marcolin, Tedone, Colombo, Mangerini, Bo, Ruzzenenti, Carlier, Serio, Luchetti, Dominietto, Varaldo, Candiani, Agostini, Ravetti, Del Zotto, Marcenaro and Lemoli 2021 Guolo, Minetto, Pesce, Ballerini, Clavio, Cea, Frello, Garibotto, Greppi, Bozzo, Miglino, Passannante, Marcolin, Tedone, Colombo, Mangerini, Bo, Ruzzenenti, Carlier, Serio, Luchetti, Dominietto, Varaldo, Candiani, Agostini, Ravetti, Del Zotto, Marcenaro and Lemoli ;ISSN: 1664-3224 ;EISSN: 1664-3224 ;DOI: 10.3389/fimmu.2021.753890 ;PMID: 34804039

Full text available

Citations Cited by
7
P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE
P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE
Material Type:
Article 		Add to My Research

P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE

HemaSphere, 2023-08, Vol.7 (S3), p.e7714084-n/a [Peer Reviewed Journal]

Copyright © 2023 The Author(s). ;Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 2572-9241 ;EISSN: 2572-9241 ;DOI: 10.1097/01.HS9.0000968432.77140.84

Full text available

Citations Cited by
8
S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION
S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION
Material Type:
Article 		Add to My Research

S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

HemaSphere, 2023-08, Vol.7 (S3), p.e4683875-n/a [Peer Reviewed Journal]

Copyright © 2023 The Author(s). ;Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 2572-9241 ;EISSN: 2572-9241 ;DOI: 10.1097/01.HS9.0000967780.46838.75

Full text available

Citations Cited by
9
P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION
P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION
Material Type:
Article 		Add to My Research

P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

HemaSphere, 2023-08, Vol.7 (S3), p.e89713c5-n/a [Peer Reviewed Journal]

Copyright © 2023 The Author(s). ;Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 2572-9241 ;EISSN: 2572-9241 ;DOI: 10.1097/01.HS9.0000969028.89713.c5

Full text available

Citations Cited by
10
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function
Material Type:
Article 		Add to My Research

Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function

Journal of translational medicine, 2019-08, Vol.17 (1), p.250-250, Article 250 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;The Author(s) 2019 ;ISSN: 1479-5876 ;EISSN: 1479-5876 ;DOI: 10.1186/s12967-019-2004-2 ;PMID: 31383037

Full text available

Citations Cited by
11
Health‐related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real‐world Study by the GIMEMA
Health‐related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real‐world Study by the GIMEMA
Material Type:
Article 		Add to My Research

Health‐related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real‐world Study by the GIMEMA

HemaSphere, 2023-09, Vol.7 (9), p.e944-n/a [Peer Reviewed Journal]

Copyright © 2023 The Author(s). ;Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. 2023 ;ISSN: 2572-9241 ;EISSN: 2572-9241 ;DOI: 10.1097/HS9.0000000000000944 ;PMID: 37663671

Full text available

Citations Cited by
12
P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML
P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML
Material Type:
Article 		Add to My Research

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

HemaSphere, 2023-08, Vol.7 (S3), p.e997112b-n/a [Peer Reviewed Journal]

Copyright © 2023 The Author(s). ;Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 2572-9241 ;EISSN: 2572-9241 ;DOI: 10.1097/01.HS9.0000969120.99711.2b

Full text available

Citations Cited by
13
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis
Material Type:
Article 		Add to My Research

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis

Cancer medicine (Malden, MA), 2019-12, Vol.8 (18), p.7567-7576 [Peer Reviewed Journal]

2019 The Authors. published by John Wiley & Sons Ltd. ;2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. ;2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2045-7634 ;EISSN: 2045-7634 ;DOI: 10.1002/cam4.2638 ;PMID: 31657156

Full text available

Citations Cited by
14
PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
Material Type:
Article 		Add to My Research

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e0109137 [Peer Reviewed Journal]

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 2572-9241 ;EISSN: 2572-9241 ;DOI: 10.1097/01.HS9.0000973828.01091.37

Full text available

Citations Cited by
15
Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients
Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients
Material Type:
Article 		Add to My Research

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Blood, 2022-11, Vol.140 (Supplement 1), p.11710-11712 [Peer Reviewed Journal]

2022 The American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2022-160127

Full text available

Citations Cited by
16
The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities
The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities
Material Type:
Article 		Add to My Research

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Blood, 2022-11, Vol.140 (Supplement 1), p.9929-9929 [Peer Reviewed Journal]

2022 The American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2022-169453

Full text available

Citations Cited by
17
Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Material Type:
Article 		Add to My Research

Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.1644-1644 [Peer Reviewed Journal]

ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2023-186819

Full text available

Citations Cited by
18
Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy
Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy
Material Type:
Article 		Add to My Research

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Blood, 2022-11, Vol.140 (Supplement 1), p.7064-7065 [Peer Reviewed Journal]

2022 The American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2022-169263

Full text available

Citations Cited by
19
Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction
Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction
Material Type:
Article 		Add to My Research

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Blood, 2023-11, Vol.142 (Supplement 1), p.6016-6016 [Peer Reviewed Journal]

ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2023-186555

Full text available

Citations Cited by
20
High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia
High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia
Material Type:
Article 		Add to My Research

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.5879-5879 [Peer Reviewed Journal]

ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2023-185082

Full text available

Citations Cited by

Results 1 - 20 of 95  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (90)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1996  (5)
  2. 1996 To 2004  (4)
  3. 2005 To 2012  (4)
  4. 2013 To 2017  (23)
  5. After 2017  (60)
  6. More options open sub menu

Resource Type 

  1. Articles  (94)
  2. Reports  (1)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait